We attened the 2205 ESMO Congress, that took place Oct 17-21, in Berlin, Germany. Review our poster and partner poster presentations below.
Featured Presentations
Scientific Posters
We were proud to share ClearNote Health’s latest breakthroughs in epigenomic-based early cancer detection and therapy monitoring, powered by our Virtuoso™ platform.
From multicancer validation data to new findings in pancreatic cancer surveillance and monitoring response to therapies, every discussion reinforced the importance of detecting cancer earlier, when treatment has the greatest impact.
Our team and partners had a total of 7 poster presentations. If you missed us at the event but would like to view our presentations, they are now available virtually. See details below.
Validation of an epigenomic-based multicancer detection test
Presenter: Dr. Stephen R. Quake, Stanford University
https://go.clearnotehealth.com/CNH-ESMO-1745P
Evaluation of a cell-free DNA-based blood test for early detection of pancreatic cancer in high-risk individuals with family history and genetic predisposition
Presenter: Dr. Randall Brand, University of Pittsburgh
https://go.clearnotehealth.com/CNH-ESMO-2245P
SAFE-D trial design: Targeted pancreatic cancer surveillance to evaluate resectability rate and stage shift in patients with new onset diabetes
Presenter: Dr. Victoria Goss, Southampton Clinical Trials Unit
https://go.clearnotehealth.com/CNH-ESMO-8561
Epigenomic Multicancer Detection Algorithms Capture Disease Biomarkers through Machine Learning
Presenter: Dr. Stephen R. Quake, Stanford University
https://go.clearnotehealth.com/CNH-ESMO-8147
Epigenomic cancer detection and the relationship with circulating tumor allele fraction
Presenter: Dr. Zaed Hamady, University Hospital Southampton
https://go.clearnotehealth.com/CNH-ESMO-246eP
Epigenomic measurement of tumor fraction contributions to cfDNA in a multicancer test
Presenter: Dr. Martin Sjöström, Lund University
https://go.clearnotehealth.com/CNH-ESMO-212eP
Epigenomic liquid biopsy for quantification of platinum and PARP inhibitor response in patients with germ line BRCA-associated PDAC
Presenter: Dr. Talia Golan, Sheba Medical Center
https://go.clearnotehealth.com/CNH-ESMO-2270eP